1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 44, 04/Nov/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We estimated SARS-CoV-2 vaccine effectiveness against onward transmission by comparing secondary attack rates among household members for vaccinated and unvaccinated index cases, based on source and contact tracing data collected when the Delta variant was dominant. Effectiveness of full vaccination of the index case against transmission to unvaccinated and fully vaccinated household contacts, respectively, was 63% (95% confidence interval (CI): 46–75) and 40% (95% CI: 20–54), in addition to the direct protection of vaccination of contacts against infection.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.44.2100977
2021-11-04
2024-12-21
/content/10.2807/1560-7917.ES.2021.26.44.2100977
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/44/eurosurv-26-44-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.44.2100977&mimeType=html&fmt=ahah

References

  1. de Gier B, Andeweg S, Joosten R, Ter Schegget R, Smorenburg N, van de Kassteele J, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. Euro Surveill. 2021;26(31):2100640.  https://doi.org/10.2807/1560-7917.ES.2021.26.31.2100640  PMID: 34355689 
  2. Netherlands to reopen further with coronavirus entry passes. The Hague: Government of the Netherlands; 2021.Available from: https://www.government.nl/latest/news/2021/09/14/netherlands-to-reopen-further-with-coronavirus-entry-passes
  3. Coronavirus variants. The Hague: Dutch government; 2021.Available from: https://coronadashboard.government.nl/landelijk/varianten
  4. Halloran ME, Préziosi MP, Chu H. Estimating vaccine efficacy from secondary attack rates. J Am Stat Assoc. 2003;98(461):38-46.  https://doi.org/10.1198/016214503388619076 
  5. Højsgaard S, Halekoh U, Yan J. The R package geepack for generalized estimating equations. J Stat Softw. 2005;15(2):1-11.
  6. National Institute for Public Health and the Environment (RIVM). Figures on the COVID-19 vaccination programme: Bilthoven: RIVM; 2021.Available from: https://www.rivm.nl/en/covid-19-vaccination/figures-vaccination-programme
  7. Sanquin bloodbank. Antistoffen bij 95% van donors. [Antibodies in 95% of donors]. Amsterdam: Sanquin; 2021. Dutch. Available from: https://www.sanquin.nl/over-sanquin/nieuws/2021/08/antistoffen-bij-95-van-donors
  8. Number of confirmed cases. The Hague: Government of the Netherlands. [Accessed: 14 October 2021]. Available from: https://coronadashboard.government.nl/landelijk/positief-geteste-mensen
  9. Liu H, Zhang J, Cai J, Deng X, Peng C, Chen X, et al. Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China. Preprint. medRxiv. 2021:2021.07.23.21261013.
  10. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-94.  https://doi.org/10.1056/NEJMoa2108891  PMID: 34289274 
  11. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission. Preprint. medRxiv. 2021:2021.09.28.21264260.
  12. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398(10308):1377-80.  https://doi.org/10.1016/S0140-6736(21)02046-8  PMID: 34534516 
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Brechje+de+Gier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Gier Brechje</a>, <a href="/search?value1=Stijn+Andeweg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Andeweg Stijn</a>, <a href="/search?value1=Jantien+A+Backer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Backer Jantien A</a>, <a href="/search?value1=RIVM+COVID-19+surveillance+and+epidemiology+team&option1=author&noRedirect=true" class="nonDisambigAuthorLink">RIVM COVID-19 surveillance and epidemiology team</a>, <a href="/search?value1=Susan+JM+Hahn%C3%A9&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hahné Susan JM</a>, <a href="/search?value1=Susan+van+den+Hof&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van den Hof Susan</a>, <a href="/search?value1=Hester+E+de+Melker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Melker Hester E</a>, <a href="/search?value1=Mirjam+J+Knol&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Knol Mirjam J</a></span>. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(44):pii=2100977. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.44.2100977" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.44.2100977</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 14 Oct 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 03 Nov 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.44.2100977
/content/10.2807/1560-7917.ES.2021.26.44.2100977
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error